Diurnal Variation of Plasminogen Activator Inhibitor-1
Completed
National Center for Research Resources (NCRR)
Phase 4
2007-04-01
To determine if nighttime administration of an aldosterone antagonist would effectively lower
peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning
administration.
Diurnal Variation of Plasminogen Activator Inhibitor-1
Completed
Vanderbilt University Medical Center
Phase 4
2007-04-01
To determine if nighttime administration of an aldosterone antagonist would effectively lower
peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning
administration.
Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg
Completed
Mylan Pharmaceuticals
Phase 1
2003-08-01
The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl
and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20mg/ 25 mg tablets
following a single, oral 20/25 mg (1 x 20/25 mg) dose administration under fed conditions.
Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg
Completed
Mylan Pharmaceuticals
Phase 1
2003-08-01
The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl
and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20 mg/25 mg tablets
following a single, oral 20 mg/25 mg (1 x 20 mg/25 mg) dose administered under fasting
conditions.
A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension
Completed
Pfizer
Phase 4
2002-12-01
The purpose of this study is to determine the response rate for the therapeutic goal
(diastolic blood pressure (BP) less than 90 mmHg and systolic BP less than 140 mmHg) at Week
6 for quinapril 20 mg and at Week 12 for quinapril 20 mg, quinapril 40 mg, and quinapril 20
mg plus hydrochlorothiazide 12.5 mg; and to determine the mean decrease in diastolic and
systolic BP measurements and the change in heart rate at Week 6 and Week 12 compared with
baseline.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
